← Leaderboards
Romi Gupta
Yale University
$2,402,166
Attributed
$2,601,488
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $457.9K · FY2018–25$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,601,488 · 6
By mechanism
R01$1,599,344 · 1
R03$603,500 · 4
R21$398,644 · 1
Top collaborators
- Narendra Wajapeyee3 shared
Most similar at Yale University
Same institution · by research overlap
- Justin Lee Cotney$8,490,000
- Se-Te Joseph Huang$1,785,576
- Peter M Glazer$37,467,142
- David Michael Merrick$5,032,019
- Mark A. Lemmon$27,011,161
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoGrowthEffective TherapyMouse ModelPublic HealthExperimental StudyTumor GrowthDiagnosisDrug TargetingMediatingGenesSmall Hairpin RnaSmall Molecule InhibitorPathway InteractionsGeneticKnock-DownTumor ProgressionWomanSamplingCancer CellInnovationCell Culture TechniquesBaseCancer Therapy
Grant awards (15)
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS$325,732
R01 · FY2025 · CA · contact PI
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS$309,446
R01 · FY2024 · CA · contact PI
A novel cellular identity regulatory pathway that drives anokis resistance-mediated TNBC growth and metastasis$148,500
R03 · FY2024 · CA · contact PI
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS$319,217
R01 · FY2023 · CA · contact PI
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS$319,217
R01 · FY2022 · CA · contact PI
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS$325,732
R01 · FY2021 · CA · contact PI
A Novel Anoikis Effector that Drives Ovarian Cancer Metastasis$74,250
R03 · FY2021 · CA · contact PI
A Novel Anoikis Effector that Drives Ovarian Cancer Metastasis$74,250
R03 · FY2020 · CA · contact PI
A NOVEL EPIGENETIC IMMUNOTHERAPY FOR OVARIAN CANCER TREATMENT$74,250
R03 · FY2020 · CA · contact PI
A DRUGGABLE CHROMATIN MODIFIER PATHWAY IN HCC$180,056
R21 · FY2019 · CA
PERSONALIZED THERAPY FOR p16-DEFICIENT MELANOMA$74,250
R03 · FY2019 · CA · contact PI
A NOVEL EPIGENETIC IMMUNOTHERAPY FOR OVARIAN CANCER TREATMENT$74,250
R03 · FY2019 · CA · contact PI
A DRUGGABLE CHROMATIN MODIFIER PATHWAY IN HCC$115,103
R21 · FY2018 · CA
A DRUGGABLE CHROMATIN MODIFIER PATHWAY IN HCC$103,485
R21 · FY2018 · CA
PERSONALIZED THERAPY FOR p16-DEFICIENT MELANOMA$83,750
R03 · FY2018 · CA · contact PI